HER2/ErbB2 antibody

Synonyms:CD340 antibody, ERBB2 antibody, HER 2 antibody, HER 2/neu antibody, HER2 antibody, MLN 19 antibody, MLN19 antibody, NEU antibody, NGL antibody, p185 antibody, p185erbB2 antibody, Proto oncogene c ErbB 2 antibody, Proto oncogene Neu antibody, TKR1 antibody
Catalogue No.:FNab03834Reactivity:Human
Host:RabbitTested Application:ELISA, WB, IHC, IF
Clonality:polyclonalIsotype:IgG
  • SPECIFICATIONS
Product Name
HER2/ErbB2 antibody
Catalogue No.
FNab03834
Size
100μg
Form
liquid
Purification
Immunogen affinity purified
Purity
≥95% as determined by SDS-PAGE
Clonality
polyclonal
Isotype
IgG
Storage
PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
Immunogen
Immunogen
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog(avian)
Alternative Names
CD340 antibody, ERBB2 antibody, HER 2 antibody, HER 2/neu antibody, HER2 antibody, MLN 19 antibody, MLN19 antibody, NEU antibody, NGL antibody, p185 antibody, p185erbB2 antibody, Proto oncogene c ErbB 2 antibody, Proto oncogene Neu antibody, TKR1 antibody
UniProt ID
P04626
Observed MW
185 kDa
Application
Tested Applications
ELISA, WB, IHC, IF
Recommended dilution
WB: 1:500-1:2000; IHC: 1:20-1:200; IF: 1:20-1:200
Validated Images
HeLa cells were subjected to SDS PAGE followed by western blot with FNab03834(ERBB2 antibody) at dilution of 1:500
Immunohistochemistry of paraffin-embedded human breast cancer using FNab03834(ERBB2 antibody) at dilution of 1:50
Immunofluorescent analysis of HeLa cells using FNab03834 (ErbB2 antibody) at dilution of 1:50 and Alexa Fluor 488-conjugated Goat Anti-Rabbit IgG(H+L)
Background
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors.